ArticleThe American journal of tropical medicine and hygiene2013
Trends in antimalarial drug use in Africa.
Article in The American journal of tropical medicine and hygiene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Identification of two genomic cryptotypes of Plasmodium malariae in Africa.PLoS neglected tropical diseases · 2026Article
- Targeted Sequencing Identifies SNPs Associated with Antimalarial Drug Resistance and the CSP Vaccine Antigen inInternational journal of molecular sciences · 2025Article
- Evolutionary Trajectory ofBiomedicines · 2025Review
- Changes in the Prevalence of Antimalarial Partner Drug Resistance Markers and Policy in 6 Sub-Saharan African Countries From 2000 to 2021: A Systematic Review.Open forum infectious diseases · 2025Article
- Prevalence of Plasmodium falciparum parasites harbouring chloroquine-resistant but not artemisinin-resistant alleles in Busia County, Western Kenya.Malaria journal · 2025Article
- Enhancing malaria elimination in high-transmission settings: the synergy of concurrent vector control and chemotherapy.Malaria journal · 2025Review
- Genome sequencing of Plasmodium malariae identifies continental segregation and mutations associated with reduced pyrimethamine susceptibility.Nature communications · 2024Article
- Prevalence of molecular markers of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from West Africa during 2012-2022.Scientific reports · 2024Article
- Genomics reveals heterogeneous Plasmodium falciparum transmission and selection signals in Zambia.Communications medicine · 2024Article
- Article
- Genomics reveals heterogeneousmedRxiv : the preprint server for health sciences · 2024Article
- Antigenic strain diversity predicts different biogeographic patterns of maintenance and decline of anti-malarial drug resistance.bioRxiv : the preprint server for biology · 2023Article
- Examining the disparities of anti-malarial drug consumption among children under the age of five: a study of 5 malaria-endemic countries.Malaria journal · 2023Article
- Ethiopian Plasmodium vivax hypnozoites formation dynamics and their susceptibility to reference antimalarial drugs.BMC infectious diseases · 2023Article
- Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990-2020.PLoS computational biology · 2022Article
- Prevalence of malaria resistance-associated mutations inFrontiers in microbiology · 2022Article
- Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Historical trends and new surveillance of Plasmodium falciparum drug resistance markers in Angola.Malaria journal · 2021Article
- Molecular surveillance of pfcrt, pfmdr1 and pfk13-propeller mutations in Plasmodium falciparum isolates imported from Africa to China.Malaria journal · 2021Article
- Chloroquine and Sulfadoxine-Pyrimethamine Resistance in Sub-Saharan Africa-A Review.Frontiers in genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) led the World Health Organization (WHO) to recommend changes in national drug policies. The time between policy changes and their implementation profoundly affects program impact. We developed a model based on data on antimalarial treatments, extracted from household surveys and national antimalarial policy information from the literature. Drug use in each country during the time period 1999-2011 and the trend in reduction of CQ use after policy change were estimated. The SP use estimates were correlated with the prevalence of a molecular marker associated with SP resistance. There was no spatial pattern in the country-level rate of reduction of CQ use, after policy change. In East Africa SP drug use was strongly correlated to resistance. If artemisinin resistance spreads to, or emerges in, Africa this methodology will be a valuable tool to estimate actual drug use and its impact on changes in drug efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.